Investor Presentaiton
Rigosertib identified as lead PLK1 inhibitor in RDEB CSCC
Translational Cancer Mechanisms and Therapy
Identification of Rigosertib for the Treatment of
Recessive Dystrophic Epidermolysis Bullosa-
Associated Squamous Cell Carcinoma
Clinical
Cancer
Research
Check for
updates
Velina S. Atanasova', Celine Pourreyron², Mehdi Farshchian', Michael Lawler',
Christian A. Brown IV, Stephen A. Watt2, Sheila Wright2, Michael Warkala',
Christina Guttmann-Gruber³, Josefina Piñón Hofbauer³, Ignacia Fuentes 4,5, Marco Prisco',
Elham Rashidghamat, Cristina Has, Julio C. Salas-Alanis, Francis Palisson 4
Alain Hovnanian 10,11, John A. McGrath, Jemima E. Mellerio, Johann W. Bauer³, and
Andrew P. South'
4,9
16
Clin Cancer Res March 7 2019 DOI:10.1158/1078-0432.CCR-18-2661. PMID: 30846478
0
ONCONOVA
THERAPEUTICSView entire presentation